Libo Yang1,2,3, Dongli Lu4, Yutian Lai5, Mengjia Shen1,2,3, Qiuxiao Yu6, Ting Lei1,2,3, Tianjie Pu1,2,3, Hong Bu7,8,9. 1. Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. 2. Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China. 3. Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, China. 4. Department of Life Sciences, Imperial College London, London, UK. 5. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 6. Department of Pathology, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. 7. Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. hongbu@scu.edu.cn. 8. Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China. hongbu@scu.edu.cn. 9. Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, China. hongbu@scu.edu.cn.
Abstract
BACKGROUND: We aimed to analyze the effects of radiotherapy (RT) on the incidence rate of ipsilateral breast event (IBE) in ductal carcinoma in situ (DCIS) patients with lumpectomy after being stratified by prognostic score. METHODS: We identified DCIS patients who received lumpectomy, from the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2015. Cumulative incidence functions for competing risk were used to evaluate the effects of RT on IBE risk over time. Three multivariate regression models (weighted, non-weighted, and Fine-Gray) were applied to compare the IBE risk between the RT and non-RT groups after stratifying patients by prognostic score. RESULTS: Overall, 72,623 DCIS patients were identified from the SEER database and 49,206 (66.8%) patients received RT. During the follow-up period (ranging from 7 to 347 months), the cumulative probability of invasive and in situ IBE was significantly lower in the RT group than in the non-RT group (p < 0.001). After being stratified by prognostic score, the weighted IBE incidence rate increased as the risk level increased (p < 0.050). In multivariate regression models, RT lowered the IBE incidence rate by at least 30% in low-, moderate-, and high-risk DCIS (p < 0.010). In particular, the in situ and invasive IBE incidence rate decreased by over 50% in low-risk DCIS with RT (p < 0.001). CONCLUSIONS: RT is associated with a lowered IBE incidence rate in DCIS patients, regardless of the assigned risk levels for patients. The significant reduction in the IBE incidence rate in low-risk DCIS patients also indicates the potential benefits for recommending RT to such a patient population in clinical practice.
BACKGROUND: We aimed to analyze the effects of radiotherapy (RT) on the incidence rate of ipsilateral breast event (IBE) in ductal carcinoma in situ (DCIS) patients with lumpectomy after being stratified by prognostic score. METHODS: We identified DCIS patients who received lumpectomy, from the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2015. Cumulative incidence functions for competing risk were used to evaluate the effects of RT on IBE risk over time. Three multivariate regression models (weighted, non-weighted, and Fine-Gray) were applied to compare the IBE risk between the RT and non-RT groups after stratifying patients by prognostic score. RESULTS: Overall, 72,623 DCIS patients were identified from the SEER database and 49,206 (66.8%) patients received RT. During the follow-up period (ranging from 7 to 347 months), the cumulative probability of invasive and in situ IBE was significantly lower in the RT group than in the non-RT group (p < 0.001). After being stratified by prognostic score, the weighted IBE incidence rate increased as the risk level increased (p < 0.050). In multivariate regression models, RT lowered the IBE incidence rate by at least 30% in low-, moderate-, and high-risk DCIS (p < 0.010). In particular, the in situ and invasive IBE incidence rate decreased by over 50% in low-risk DCIS with RT (p < 0.001). CONCLUSIONS: RT is associated with a lowered IBE incidence rate in DCIS patients, regardless of the assigned risk levels for patients. The significant reduction in the IBE incidence rate in low-risk DCIS patients also indicates the potential benefits for recommending RT to such a patient population in clinical practice.
Authors: Tawakalitu O Oseni; Biqi Zhang; Suzanne B Coopey; Michele A Gadd; Kevin S Hughes; David C Chang Journal: J Am Coll Surg Date: 2019-02-15 Impact factor: 6.113
Authors: Valerie Cui Yun Koh; Jeffrey Chun Tatt Lim; Aye Aye Thike; Poh Yian Cheok; Minn Minn Myint Thu; Veronique Kiak Mien Tan; Benita Kiat Tee Tan; Kong Wee Ong; Gay Hui Ho; Wai Jin Tan; Yongcheng Tan; Ahmed Syed Salahuddin; Inny Busmanis; Angela Pek Yoon Chong; Jabed Iqbal; Shyamala Thilagaratnam; Jill Su Lin Wong; Puay Hoon Tan Journal: Breast Cancer Res Treat Date: 2015-06-16 Impact factor: 4.872
Authors: Marc D Ryser; Donald L Weaver; Fengmin Zhao; Mathias Worni; Lars J Grimm; Roman Gulati; Ruth Etzioni; Terry Hyslop; Sandra J Lee; E Shelley Hwang Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: I A Olivotto; C Bancej; V Goel; J Snider; R G McAuley; B Irvine; L Kan; D Mirsky; M J Sabine; R McGilly; J S Caines Journal: CMAJ Date: 2001-08-07 Impact factor: 8.262
Authors: Karla Kerlikowske; Annette Molinaro; Imok Cha; Britt-Marie Ljung; Virginia L Ernster; Kim Stewart; Karen Chew; Dan H Moore; Fred Waldman Journal: J Natl Cancer Inst Date: 2003-11-19 Impact factor: 13.506
Authors: Lotte E Elshof; Michael Schaapveld; Emiel J Rutgers; Marjanka K Schmidt; Linda de Munck; Flora E van Leeuwen; Jelle Wesseling Journal: Breast Cancer Res Date: 2017-03-09 Impact factor: 6.466
Authors: Lotte E Elshof; Marjanka K Schmidt; Emiel J Th Rutgers; Flora E van Leeuwen; Jelle Wesseling; Michael Schaapveld Journal: Ann Surg Date: 2018-05 Impact factor: 12.969
Authors: Maartje van Seijen; Esther H Lips; Alastair M Thompson; Serena Nik-Zainal; Andrew Futreal; E Shelley Hwang; Ellen Verschuur; Joanna Lane; Jos Jonkers; Daniel W Rea; Jelle Wesseling Journal: Br J Cancer Date: 2019-07-09 Impact factor: 7.640